Immunological complications beyond rejection after intestinal transplantation

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Intestinal transplantation (ITx) represents a major immunological challenge as the bidirectional exchange of donor's and recipient's immune cells delivers a graft highly chimeric and immunogenic. Therefore, there is a higher risk for immunological complications. It is important to understand the prevalence, natural history and mechanisms of other immunological complications, beyond rejection, to better understand the implications of ITx. RECENT FINDINGS: In recent studies, graft-versus-host disease (GVHD) holds a high mortality (43-70%). Apart from increasing or modifying immunosuppression, there are not other new therapies at this time. Inflammatory bowel disease (IBD) in solid organ transplant recipients has been estimated to be 10 times that of the general population. In the ITx recipient, it is not clear whether IBD is an autonomous disorder or a different phenotype of acute rejection. There are some studies suggesting that anti-tumour necrosis factor α (anti-TNFα) may have a role in preventing or treating rejection. According to recent studies, the incidence of autoimmune hemolytic anemia is 11% and a large proportion of these patients will respond to conventional therapy. SUMMARY: Rejection, GVHD, IBD-like disorder, autoimmune disorders and food allergies are among the more significant immunological complications after ITx. We need further studies to comprehend the risk factors and pathophysiology that will lead to better markers and innovative therapies that will impact survival.

Original languageEnglish (US)
Pages (from-to)268-272
Number of pages5
JournalCurrent opinion in organ transplantation
Volume17
Issue number3
DOIs
StatePublished - Jun 1 2012

Fingerprint

Inflammatory Bowel Diseases
Transplantation
Graft vs Host Disease
Transplants
Autoimmune Hemolytic Anemia
Investigational Therapies
Food Hypersensitivity
Natural History
Immunosuppression
Cohort Studies
Tumor Necrosis Factor-alpha
Tissue Donors
Phenotype
Survival
Mortality
Therapeutics
Population

Keywords

  • autoimmune hemolytic anemia
  • autoimmune hepatitis
  • food allergy
  • graft-versus-host disease
  • inflammatory bowel disease

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Immunological complications beyond rejection after intestinal transplantation. / Quiros, Ruben.

In: Current opinion in organ transplantation, Vol. 17, No. 3, 01.06.2012, p. 268-272.

Research output: Contribution to journalReview article

@article{016ed87055c94e459be8ca7affae0afd,
title = "Immunological complications beyond rejection after intestinal transplantation",
abstract = "PURPOSE OF REVIEW: Intestinal transplantation (ITx) represents a major immunological challenge as the bidirectional exchange of donor's and recipient's immune cells delivers a graft highly chimeric and immunogenic. Therefore, there is a higher risk for immunological complications. It is important to understand the prevalence, natural history and mechanisms of other immunological complications, beyond rejection, to better understand the implications of ITx. RECENT FINDINGS: In recent studies, graft-versus-host disease (GVHD) holds a high mortality (43-70{\%}). Apart from increasing or modifying immunosuppression, there are not other new therapies at this time. Inflammatory bowel disease (IBD) in solid organ transplant recipients has been estimated to be 10 times that of the general population. In the ITx recipient, it is not clear whether IBD is an autonomous disorder or a different phenotype of acute rejection. There are some studies suggesting that anti-tumour necrosis factor α (anti-TNFα) may have a role in preventing or treating rejection. According to recent studies, the incidence of autoimmune hemolytic anemia is 11{\%} and a large proportion of these patients will respond to conventional therapy. SUMMARY: Rejection, GVHD, IBD-like disorder, autoimmune disorders and food allergies are among the more significant immunological complications after ITx. We need further studies to comprehend the risk factors and pathophysiology that will lead to better markers and innovative therapies that will impact survival.",
keywords = "autoimmune hemolytic anemia, autoimmune hepatitis, food allergy, graft-versus-host disease, inflammatory bowel disease",
author = "Ruben Quiros",
year = "2012",
month = "6",
day = "1",
doi = "10.1097/MOT.0b013e32835337b2",
language = "English (US)",
volume = "17",
pages = "268--272",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Immunological complications beyond rejection after intestinal transplantation

AU - Quiros, Ruben

PY - 2012/6/1

Y1 - 2012/6/1

N2 - PURPOSE OF REVIEW: Intestinal transplantation (ITx) represents a major immunological challenge as the bidirectional exchange of donor's and recipient's immune cells delivers a graft highly chimeric and immunogenic. Therefore, there is a higher risk for immunological complications. It is important to understand the prevalence, natural history and mechanisms of other immunological complications, beyond rejection, to better understand the implications of ITx. RECENT FINDINGS: In recent studies, graft-versus-host disease (GVHD) holds a high mortality (43-70%). Apart from increasing or modifying immunosuppression, there are not other new therapies at this time. Inflammatory bowel disease (IBD) in solid organ transplant recipients has been estimated to be 10 times that of the general population. In the ITx recipient, it is not clear whether IBD is an autonomous disorder or a different phenotype of acute rejection. There are some studies suggesting that anti-tumour necrosis factor α (anti-TNFα) may have a role in preventing or treating rejection. According to recent studies, the incidence of autoimmune hemolytic anemia is 11% and a large proportion of these patients will respond to conventional therapy. SUMMARY: Rejection, GVHD, IBD-like disorder, autoimmune disorders and food allergies are among the more significant immunological complications after ITx. We need further studies to comprehend the risk factors and pathophysiology that will lead to better markers and innovative therapies that will impact survival.

AB - PURPOSE OF REVIEW: Intestinal transplantation (ITx) represents a major immunological challenge as the bidirectional exchange of donor's and recipient's immune cells delivers a graft highly chimeric and immunogenic. Therefore, there is a higher risk for immunological complications. It is important to understand the prevalence, natural history and mechanisms of other immunological complications, beyond rejection, to better understand the implications of ITx. RECENT FINDINGS: In recent studies, graft-versus-host disease (GVHD) holds a high mortality (43-70%). Apart from increasing or modifying immunosuppression, there are not other new therapies at this time. Inflammatory bowel disease (IBD) in solid organ transplant recipients has been estimated to be 10 times that of the general population. In the ITx recipient, it is not clear whether IBD is an autonomous disorder or a different phenotype of acute rejection. There are some studies suggesting that anti-tumour necrosis factor α (anti-TNFα) may have a role in preventing or treating rejection. According to recent studies, the incidence of autoimmune hemolytic anemia is 11% and a large proportion of these patients will respond to conventional therapy. SUMMARY: Rejection, GVHD, IBD-like disorder, autoimmune disorders and food allergies are among the more significant immunological complications after ITx. We need further studies to comprehend the risk factors and pathophysiology that will lead to better markers and innovative therapies that will impact survival.

KW - autoimmune hemolytic anemia

KW - autoimmune hepatitis

KW - food allergy

KW - graft-versus-host disease

KW - inflammatory bowel disease

UR - http://www.scopus.com/inward/record.url?scp=84861187220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861187220&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e32835337b2

DO - 10.1097/MOT.0b013e32835337b2

M3 - Review article

C2 - 22476219

AN - SCOPUS:84861187220

VL - 17

SP - 268

EP - 272

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 3

ER -